{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:11:27Z","timestamp":1788315087210,"version":"build-2803163510"},"reference-count":16,"publisher":"Danish Medical Association","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ugeskr L\u00e6ger"],"abstract":"<jats:p>Ulcerative colitis and Crohn's disease are chronic inflammatory bowel diseases. Recent pivotal phase 3 trials involving treatments like interleukin-23-, sphingosin-1-phosphate- and Janus kinase inhibitors have demonstrated notable effectiveness. However, they have also unveiled significant side effects such as herpes zoster, lymphopenia and bradycardia. The introduction of novel treatments raises valid concerns necessitating increased collaboration with diverse medical specialities to address potentially severe side effects, and this is vital for enhancing the future care of individuals with inflammatory bowel diseases, as argued in this review.<\/jats:p>","DOI":"10.61409\/v11230688","type":"journal-article","created":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T06:17:20Z","timestamp":1715667440000},"page":"1-6","source":"Crossref","is-referenced-by-count":1,"title":["Biologics and targeted synthetic medicines for ulcerative colitis and Crohn's disease"],"prefix":"10.61409","author":[{"given":"Anna Lyngs\u00f8","family":"Bliampti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob Benedict","family":"Seidelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Burisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"40208","published-online":{"date-parts":[[2024,4,29]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Dorn-Rasmussen M, Lo B, Zhao M et al. The incidence and prevalence of paediatric-and adult-onset inflammatory bowel disease in Denmark during a 37-year period: a nationwide cohort study (1980-2017). J Crohns Colitis. 2023;17:259-268. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjac138","DOI":"10.1093\/ecco-jcc\/jjac138"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Magro F, Afonso J, Lopes S et al. Calprotectin and the magnitude of antibodies to infliximab in clinically-stable ulcerative colitis patients are more relevant than infliximab through levels and pharmacokinetics for therapeutic escalation. EBioMedicine. 2017;21:123-130. doi: https:\/\/doi.org\/10.1016\/j.ebiom.2017.06.004","DOI":"10.1016\/j.ebiom.2017.06.004"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"D'Haens GR, Van Deventer S. 25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future. Gut. 2021;70(7):1396-1405. https:\/\/doi.org\/10.1136\/gutjnl-2019-320022","DOI":"10.1136\/gutjnl-2019-320022"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"D'Haens G, Dubinsky M, Kobayashi T et al. Mirikizumab as induction and maintenance therapy for ulcerative colitis. New Engl J Med. 2023;388(26):2444-2455. https:\/\/doi.org\/10.1056\/NEJMoa2207940","DOI":"10.1056\/NEJMoa2207940"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Sands BE, Sandborn WJ, Panaccione R et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. New Engl J Med. 2019;381(13):1201-1214. https:\/\/doi.org\/10.1056\/NEJMoa1900750","DOI":"10.1056\/NEJMoa1900750"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Sandborn WJ, Su C, Sands BE et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. New Engl J Med. 2017;376(18):1723-1736. https:\/\/doi.org\/10.1056\/NEJMoa1606910","DOI":"10.1056\/NEJMoa1606910"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Danese S, Vermeire S, Zhou W et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022;399(10341):2113-2128. https:\/\/doi.org\/10.1016\/S0140-6736(22)00581-5","DOI":"10.1016\/S0140-6736(22)00581-5"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Feagan BG, Danese S, Loftus EV et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial. Lancet. 2021;397(10292):2372-2384. https:\/\/doi.org\/10.1016\/S0140-6736(21)00666-8","DOI":"10.1016\/S0140-6736(21)00666-8"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Winthrop KL, Cohen SB. Oral surveillance and JAK inhibitor safety: the theory of relativity. https:\/\/doi.org\/10.1038\/s41584-022-00767-7","DOI":"10.1038\/s41584-022-00767-7"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Feagan BG, Sands BE, Sandborn WJ et al. Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial. Lancet Gastroenterol Hepatol. 2023;8(4):307-320. https:\/\/doi.org\/10.1016\/S2468-1253(22)00427-7","DOI":"10.1016\/S2468-1253(22)00427-7"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Feagan BG, Sandborn WJ, Gasink C et al. Ustekinumab as induction and maintenance therapy for Crohn's disease. New Engl J Med. 2016;375(20):1946-1960https:\/\/doi.org\/10.1056\/NEJMoa1602773","DOI":"10.1056\/NEJMoa1602773"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"D'Haens G, Panaccione R, Baert F et al. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022;399(10340):2015-2030. https:\/\/doi.org\/10.1016\/S0140-6736(22)00467-6","DOI":"10.1016\/S0140-6736(22)00467-6"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Sandborn WJ, Feagan BG, D'Haens G et al. Ozanimod as induction and maintenance therapy for ulcerative colitis. New Engl J Med. 2021;385(14):1280-1291. https:\/\/doi.org\/10.1056\/NEJMoa2033617","DOI":"10.1056\/NEJMoa2033617"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Vermeire S, Danese S, Zhou W et al. Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study. Lancet Gastroenterol Hepatol. 2023;8(11):976-989. https:\/\/doi.org\/10.1016\/S2468-1253(23)00208-X","DOI":"10.1016\/S2468-1253(23)00208-X"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Loftus EV Jr, Pan\u00e9s J, Lacerda AP et al. Upadacitinib induction and maintenance therapy for Crohn's disease. New Engl J Med. 2023;388(21):1966-1980. https:\/\/doi.org\/10.1056\/NEJMoa2212728","DOI":"10.1056\/NEJMoa2212728"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Torres J, Chaparro M, Julsgaard M et al. European Crohn's and colitis guidelines on sexuality, fertility, pregnancy, and lactation. J Crohns Colitis. 2023;17(1):1-27. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjac115","DOI":"10.1093\/ecco-jcc\/jjac115"}],"container-title":["Ugeskrift for L\u00e6ger"],"original-title":[],"deposited":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T06:44:46Z","timestamp":1723445086000},"score":1,"resource":{"primary":{"URL":"https:\/\/ugeskriftet.dk\/videnskab\/V11230688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,29]]},"references-count":16,"URL":"https:\/\/doi.org\/10.61409\/v11230688","relation":{},"ISSN":["0041-5782","1603-6824"],"issn-type":[{"value":"0041-5782","type":"print"},{"value":"1603-6824","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,29]]}}}